1-(3-p-Tolylisoxazol-5-yl)cyclohexanol

1-(3-p-Tolyl­isoxazol-5-yl)cyclo­hexa­nol

The title compound, C(16)H(19)NO(2), contains two mol-ecules in the asymmetric unit. Each mol-ecule is composed of three inter-connected rings, two essentially planar rings, viz. the isoxazole and the methyl-benzyl aromatic ring [maximum deviations of 0.0027 (13) and 0.0031 (19) Å from the isoxazole and methylbenzyl ring planes, respectively, in the first molecule, 0.0018 (12) and 0.019 (2) Å i...

PYRAZOLINES AND ISOXAZOLINES (I). SYNTHESIS AND ANTIMICROBIAL ACTIVITIES OF P-(1-ACYL-3-METHYL-5-ARYL-4 PYRAZOLINOYL / P-(3-METHYL-5-ARYL-4ISOXAZOLINOYL) ARSANILIC ACID

4-(acetoacetamido) arsanilic acid (II), which was then condensed with aryl aldehydes. The resulting product on reaction with hydrazine hydrate and hydroxyl amine hydrochloride yielded Pyrazolines (IV) and Isoxazolines (V), respectively. The antimicrobial activity of compounds against a number of microorganisms was evaluated. Some of these compounds showed significant antimicrobial activity

3 Prime { P 5 , P 5 , C 5 } - free graphs

We prove that a graph G contains no induced 5-vertex path and no induced complement of a 5-vertex path if and only if G is obtained from 5-cycles and split graphs by repeatedly applying the following operations: substitution, split unification, and split unification in the complement (where split unification is a new class-preserving operation that is introduced in this paper).

pyrazolines and isoxazolines (i). synthesis and antimicrobial activities of p-(1-acyl-3-methyl-5-aryl-4 pyrazolinoyl / p-(3-methyl-5-aryl-4isoxazolinoyl) arsanilic acid

4-(acetoacetamido) arsanilic acid (ii), which was then condensed with aryl aldehydes. the resulting product on reaction with hydrazine hydrate and hydroxyl amine hydrochloride yielded pyrazolines (iv) and isoxazolines (v), respectively. the antimicrobial activity of compounds against a number of microorganisms was evaluated. some of these compounds showed significant antimicrobial activity

Ins ( 1 , 4 , 5 ) P and cardiac dysfunction 3